Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : KAD101
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : Northway Biotechpharma
Deal Size : Undisclosed
Deal Type : Agreement
Northway Biotech, Kaida BioPharma Ink Manufacturing Deal for KAD101 Oncology Drug
Details : Under the agreement, Northway will initiate the production of Kaida's lead product candidate, KAD101, which is being evaluated for the treatment of ovarian cancer.
Product Name : KAD101
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
May 21, 2025
Lead Product(s) : KAD101
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Northway Biotechpharma
Deal Size : Undisclosed
Deal Type : Agreement